Affymax Extends Gains

Affymax Inc. (Nasdaq: AFFY) extended its gains by rising 17 cents to $1.43 after a Seeking Alpha article said yesterday that the biopharmaceutical would successfully address safety concerns of its anemia treatment Omontys.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here